Cohort 1 (NSCLC cohort) \r\n* In regards to administration of prior anti-PD-1 or anti PD-L1 antibodies, a patients:\r\n** Must not have experienced a toxicity that led to permanent discontinuation of prior immunotherapy\r\n** All adverse events (AEs) while receiving prior immunotherapy must have completely resolved or resolved to baseline prior to screening for this study\r\n** Must not have experienced a >= grade 3 immune related AE or an immune related neurologic or ocular AE of any grade while receiving prior immunotherapy; NOTE: subjects with endocrine AE of =< grade 2 are permitted to enroll if they are stably maintained on appropriate replacement therapy and are asymptomatic\r\n** Must not have required the use of additional immunosuppression other than corticosteroids for the management of an AE, not have experienced recurrence of an AE if re-challenged, and not currently require maintenance doses of > 10 mg prednisone or equivalent per day\r\n* Eligibility for Food and Drug Administration (FDA)-approved agents targeting the EGFR, ROS1 or ALK pathway, which should be evaluated as per standard of care; exceptions to this requirement may be considered on a case-by-case basis by the principal investigator if the patient was previously treated with another targeted agent
All adverse events grade > 1 related to prior therapies (chemotherapy, radiotherapy, and/or surgery) must be resolved, except for alopecia
Corticosteroids: If used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid
Patients who had prior grade 3 or higher immune-related adverse event (e.g. pneumonitis, hepatitis, colitis, endocrinopathy) with prior immunotherapy (e.g. cancer vaccine, cytokine, etc.) are not eligible
No major surgery within 21 days of registration with stabilization or resolution of surgical adverse events
All adverse events associated with any prior surgery and intravesical therapy must have resolved to grade =< 2 prior to registration
Any prior >= grade 4 immune-related adverse event while receiving immunotherapy; patients will be excluded if experiencing any unresolved grade 3 immune related adverse events at the time of study entry; participants with a history of hypersensitivity to compounds of similar biologic composition to tremelimumab or any constituent of the product
Adverse events from prior anti-cancer therapy that have not resolved to Grade ? 1. Clinically stable patients with manageable immune-related adverse events resulting from prior cancer immunotherapy may be eligible for the study.
History of severe adverse events, in the investigator's opinion, related to ramucirumab.
Resolution or stabilization of clinically significant adverse events from prior therapy (completed at least 14 days prior to first dose of talimogene laherparepvec [TVEC])
Patient has not recovered from adverse events due to chemotherapy, immunotherapy, or radiation therapy administered more than 28 days prior to first administration of study drug.
Participants must have recovered to grade =< 1 or pretreatment baseline from clinically significant adverse events related to prior therapy (exclusions include but are not limited to alopecia, laboratory values listed per inclusion criteria and lymphopenia)
Prior chemotherapy or immunotherapy (tumor vaccine, cytokine, or growth factor given to control the cancer) must have been completed at least 4 weeks before study drug administration, and all adverse events (AEs) have either returned to baseline or stabilized
All prior anti-cancer treatment-related toxicities (except alopecia and laboratory values) must be =< grade 1 according to the Common Terminology Criteria for Adverse Events version 4 (CTCAE version 4.0) at the time of randomization, subjects with endocrinopathies (e.g. hypopituitarism, hypothyroidism, hypoadrenalism) caused by immune therapies currently on adequate hormone replacement WILL be permitted, subjects with endocrinopathies (e.g. hypopituitarism, hypothyroidism, hypoadrenalism) caused by immune therapies currently on adequate hormone replacement WILL be permitted
Grade 2 or greater toxicities due to previous therapies, subject to laboratory abnormalities listed below. Stable, tolerable Grade 2 adverse events may be allowed at discretion of Investigator
Participants who have received treatment with a TKI within 7 days of the first dose of study treatment; (an alternative appropriate wash-out time based on known duration and time to reversibility of drug related adverse events could be agreed upon by principal investigator and the investigator
Creatinine less than or equal to 1.5 x institutional upper limit of normal (ULN), equivalent to the active version of the NCI adverse event (AE) grade 1
Participants must not have experienced a grade >= 3 immune-related adverse event (AE) or an immune-related neurologic or ocular AE of any grade while receiving prior immunotherapy, or experienced a toxicity of any grade that led to permanent discontinuation of prior immunotherapy as a result of the toxicity. Participants with prior endocrine adverse events of grade =< 2 are permitted to enroll if stably maintained on appropriate replacement therapy and are asymptomatic. In the setting of prior immune-related AE, participants must not have required the use of additional immunosuppressive agents other than corticosteroids for the management of the adverse event(s), not have experienced recurrence of the adverse event if re-challenged, and not currently requiring maintenance doses of > 10 mg of prednisone or equivalent per day at the time of enrollment.
Unresolved or unstable, serious adverse events from prior administration of another investigational drug.
Any adverse events related to previous therapies for breast cancer that have not resolved to ?Grade 1.
Prior chemotherapy or immunotherapy (tumor vaccine, cytokine, or growth factor given to control the cancer: systemic or IT) must have been completed at least 4 weeks prior to enrollment and all adverse events have either returned to baseline (or resolved to < grade 1); note: subjects who have received prior platinum therapy are eligible irrespective of their response.
Washout of at least 3 weeks from prior chemotherapy or targeted therapy that induces myelosuppression and recovery of treatment related adverse events to grade 1 or less, with the exception of alopecia, is required prior to the start of palbociclib
History of grade 4 immune-related adverse events requiring treatment with prednisone, or grade 3 immune-related adverse events requiring prednisone > 10 mg/kg for > 12 weeks, if previously treated with ipilimumab
Patient has not recovered (i.e., =< grade 1 or baseline) from adverse events due to prior anti-cancer therapy;\r\n* Note: patients with =< grade 2 neuropathy are eligible
Has had prior chemoembolization, bland embolization, radioembolization, local ablative therapies, radiation to liver tumors, or major surgery such as liver resection within 4 weeks prior to study enrollment or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to intervention more than 4 weeks earlier
History of severe immune-related adverse effects from CEA-IL2v or anti-PD-1 (nivolumab, pembrolizumab) or anti-PD-L1 (atezolizumab) therapies (Common Terminology Criteria for Adverse Events Grade 3 and 4)
Any prior grade >= 3 immune related adverse events immune-mediated adverse events (imAE) while receiving immunotherapy, including anti-cytotoxic T-lymphocyte protein 4 (CTLA4) treatment, or any unresolved imAE > grade 1; Note: active or history of vitiligo will not be a basis for exclusion
Cohort A and C only: Intolerance or serious adverse immune related adverse events (irAEs) that were symptomatic or required or continues to require ongoing immunosuppression to previous immune checkpoint therapy.
Subject has not recovered from adverse reactions to prior cancer treatment or procedures (surgery, chemotherapy, immunotherapy, radiation therapy) to CTCAE Grade 2 or better.
Systemic anti-cancer treatment within 2 weeks, and all ongoing adverse events resolved to grade ? 1
In immunotherapy pretreated patients, any history of dose-limiting toxicity with prior immunotherapy agents, including grade 3/4 immune-related adverse events (irAEs); irreversible irAEs; grade >= 3 irAEs that did not respond to steroid rescue; or neurologic irAE with significant clinical sequelae
Had a prior anti-cancer monoclonal antibody (other than pembrolizumab) within 30 days prior to start of study treatment, or failure to recover to CTCAE Grade 1 or better from the adverse events of prior therapies
Must have recovered (i.e., adverse event [AE] =< grade 1 or stable) from AEs due to a previously administered agent
Grade 3 or 4 non-hematological, treatment-related adverse event (AE)s
Prior treatment with immune checkpoint inhibitors is allowed, provided that no treatment-related grade >= 3 adverse events (other than grade 3 endocrinopathy managed with replacement therapy) were observed and at least a minimum of 28 days have elapsed between the last dose of prior treatment and the proposed cycle 1 day 1
Patients with history of any Grade 3 or Grade 4 adverse events from prior ipilimumab therapy, if administered in the past.
Patients who have previously received a-PD-1 and/or anti-CTLA-4 will be eligible, unless they have ongoing > grade 2 adverse event (AE) side effects of such therapy. Ongoing physiologic replacement doses for adrenal and thyroid insufficiency are allowed on protocol
Must have recovered (i.e., =< grade 1 or at baseline) from adverse events of any previous treatment; note: surgical resection for recurrent tumor prior to enrollment is allowed
Ongoing or recent (within 5 years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments, which may suggest risk for immune-related adverse events
History of grade 4 immune-related adverse events requiring treatment with prednisone or history of grade 3 immune-related adverse events requiring prednisone > 10 mg/kg for > 12 weeks
Has experienced immune-related adverse events (AEs) (irAEs) while receiving prior immunotherapy (including anti-CTLA4 treatment) and assessed as CTCAE grade >= 3
Prior therapies for metastatic melanoma are allowed, including chemo-, cytokine-, immuno, biological and vaccine-therapy as long as they did not include BRAFi, MEKi; prior ipilimumab or PD-1 directed therapy will be allowed with a washout period of 4 weeks and if all autoimmune adverse events have resolved to grade 1 (except endocrine abnormalities that require continuous replacement)
Previous cytotoxic chemotherapy must have been completed at least 3 weeks and radiotherapy at least 2 weeks prior to day 1 of treatment on the study, and all adverse events (excluding alopecia) due to agents administered more than 4 weeks earlier should have recovered to < grade 1; participants with hematologic malignancies are expected to have hematologic abnormalities at study entry; hematologic abnormalities that are thought to be primarily related to leukemia are not considered to be toxicities (adverse events [AE]) and do not need to resolve to < grade 1
Prior chemotherapy < 2 weeks prior to study drug treatment and treatment related adverse events that have not recovered to baseline or grade 1 (alopecia excluded); prior radiation therapy < 4 weeks prior to study drug treatment
Subjects who have received investigational or approved oral or “targeted” agents (such as spleen tyrosine kinase [SYK], phosphatidylinositol 3 kinase [PI3K], B-cell chronic lymphocytic leukemia [CLL]/lymphoma 2 [bcl-2], BTK inhibitors) or lenalidomide within 1 week prior to entering the study or those whose adverse events due to agents administered more than 1 week earlier have not recovered to =< grade 1; this excludes hematologic adverse events
Patient has not recovered to grade 0-1 from adverse events due to prior chemotherapy, radiation, or biological cancer therapy (including monoclonal antibody [mAb])
Have a history of intolerance, hypersensitivity, or treatment discontinuation due to severe immune adverse events on prior immunotherapy, or documented presence of neutralizing anti-drug antibody to nivolumab, ipilimumab, or pembrolizumab. Subjects who discontinued prior immunotherapies for immune-related adverse events that are well-controlled with appropriate treatment may be enrolled if approved by the Medical Monitor.
Unresolved immune-related adverse events following prior biological therapy
Full resolution of ipilimumab related adverse events (AEs) to baseline (including immune related adverse events [irAEs]) off of steroid treatment (> 10 mg/day prednisone or equivalent dose) for irAEs for at least two weeks prior to first dose of study drug\r\n* No history of severe irAEs from ipilimumab of Common Terminology Criteria for Adverse Events (CTCAE) grade 4 requiring steroid treatment; no history of CTCAE grade 3 requiring steroid treatment (> 10 mg/day prednisone or equivalent dose) for > 12 weeks\r\n* Minimum of four weeks (wash out period) from the last dose of ipilimumab
Experiencing CTCAE grade >1 events, experienced immune-related grade ?3AEs with prior immunotherapy
Has had a prior monoclonal antibody (mAb) within 4 weeks prior to Study Day 1 or who has not recovered (i.e. ? Grade1 1 or at baseline) from acute adverse events from prior mAb therapy NOTE: Subjects with ? Grade 2 neuropathy or Grade 2 alopecia are an exception to this criterion and may qualify for the study. Investigators should discuss individual cases with the Medical Monitor or Sponsor as needed;
History of immune-related adverse event from prior immunotherapy treatment that has not improved to grade 0-1; subjects with grade 2 hypothyroidism and grade 2 adrenal insufficiency requiring continued medical treatment may enroll provided that they are asymptomatic and stable on their dose of hormone replacement
Unresolved immune-related adverse events following prior biological therapy. Subjects with asymptomatic endocrinopathy may enroll.
Previous discontinuation of treatment with deferiprone or deferoxamine due to adverse events;
Past discontinuation of bortezomib due to associated grade 3 or higher adverse event
Any grade 3-4 adverse event related to HSV-Tk infusion or a grade 2 adverse event that does not resolve to no more than grade 1 before the next infusion
Ongoing or recent evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments, which may suggest risk of immune-related treatment-emergent adverse events (irTEAEs)
Adverse events resulting from previous therapies have not recovered to grade 1 or less
Patients with any of the following adverse events at the time of enrollment are not eligible:\r\n*Grade ? 3 hyponatremia (serum Na ? 130 mmol/L)
If received prior immunotherapy must not have experienced one of the following:\r\n* A toxicity that led to permanent discontinuation of prior immunotherapy\r\n* All adverse events (AEs) while receiving prior immunotherapy must have completely resolved or resolved to baseline prior to screening for this study\r\n* Must not have experienced a >= grade 3 immune related AE or an immune related neurologic or ocular AE of any grade while receiving prior immunotherapy; NOTE: Patients with endocrine AE of =< grade 2 are permitted to enroll if they are stably maintained on appropriate replacement therapy and are asymptomatic\r\n* Must not have required the use of additional immunosuppression other than corticosteroids for the management of an AE and must not have experienced recurrence of an AE if re-challenged
Any prior grade >/= 3 immune-related adverse event (imAE) while receiving any previous immunotherapy agent, or any unresolved imAE > grade 1
Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1 excepting alopecia, peripheral sensory neuropathy, and stable endocrine insufficiencies such as thyroid and adrenal insufficiency)
Residual adverse events due to previously administered agents (except alopecia, stable residual neuropathy, and residual hand, foot syndrome) that have not recovered to Grade 1 or below in severity level (based on NCI CTCAE) before Screening
Any patient who has not recovered (i.e., =< grade 1 or at baseline) from adverse events or complications due to a previously administered systemic agent, radiation therapy, or major surgery\r\n* Exceptions: \r\n** Subjects with =< grade 2 neuropathy, hot flashes, or hypertension may qualify for the study if all other eligibility criteria met\r\n** Other toxicity or complications that are deemed by the treating investigator as not clinically significant (e.g., urinary incontinence from past prostatectomy)
Previous cytotoxic chemotherapy must have been completed at least 3 weeks and radiotherapy at least 2 weeks prior to day 1 of treatment on the study and all adverse events (excluding alopecia, acne, rash) due to agents administered more than 3 weeks earlier should have recovered to =< grade 1; patients with hematologic malignancies are expected to have hematologic abnormalities at study entry; these abnormalities which are thought to be primarily related to the underlying leukemia, are not considered to be toxicities (adverse event [AE]) and do not need to resolve to =< grade 1
The corticosteroids prednisone and dexamethasone may be continued until the day before treatment start if all related adverse events are controlled at CTCAE version 4.03 grade =< 1
Prior chemotherapy or immunotherapy (tumor vaccine, cytokine, or growth factor given to control the cancer) must have been completed at least 4 weeks before study drug administration, and all adverse events have either returned to baseline or stabilized
Has had prior anti-myeloma therapy within 2 weeks prior to study start and has not recovered (i.e., ? Grade 1 or at Baseline) from adverse events due to a previously administered agent
Adverse events from prior anti-cancer therapy that have not resolved to Grade less than or equal to (</=) 1 except for alopecia or endocrinopathy managed with replacement therapy
Ongoing medically significant adverse events from previous treatment, regardless of the time period
Adverse event due to cancer therapy administered more than 28 days prior to enrollment that has not recovered to CTCAE grade 1 or better.
Adverse events except for sensory neuropathy from any previous treatments must be resolved or stabilized to Grade less than equal to (</=) 2 prior study start
Patients may begin BBI608 on a date determined by the investigator and medical monitor for the sponsor after a minimum of 14 days since last receiving anti-cancer treatment which did not include BBI608, provided that all treatment-related adverse events have resolved or have been deemed irreversible (except for alopecia).
Prior chemotherapy or immunotherapy (tumor vaccine, cytokine, or growth factor given to control the cancer) must have been completed at least 4 weeks before study drug administration, and all adverse events have either returned to baseline or stabilized
Has not recovered from adverse events to ? Grade 1 or prior treatment level due to a previously administered agent
Grade 3-4 adverse event (AE) associated with prior anti-VEGF therapy; grade 3 hypertension that was readily managed will be permitted
Subjects previously treated with anti-program death-1 (PD1) or anti-cytotoxic T-lymphocyte associated antigen 4 (CTLA-4) antibodies must not have discontinued therapy due to any treatment-related adverse events including immune-related adverse events. Prior treatment-related adverse events should also be fully resolved and not requiring treatment for at least 28 days prior to randomization.
A history of Grade ?3 immune-related adverse event regardless of offending agent.
Clinically significant persistent immune-related adverse events following prior therapy.
All adverse events related to prior therapies (chemotherapy, radiotherapy, and/or surgery) must be resolved to =< grade 1, except for alopecia
Administration of the radioisotope, 18-FLT, which is being concurrently investigated on an imaging study within the Pediatric Brain Tumor Consortium (PBTC), is allowed > 72 hours prior to initiation of pomalidomide on this study; any adverse events related to the FLT must have resolved completely
Radiation therapy (or other non-systemic therapy) within 2 weeks prior to randomization or not fully recovered from adverse events due to a previously administered treatment
Patients receiving chemotherapy or radiotherapy within 4 weeks of injection of HF10, or history of Grade 4 adverse events or presence of adverse events Grade 2 or greater, except alopecia, resulting from anticancer agents administered more than 4 weeks prior to HF10 injection.
Patients who have not recovered from serious adverse events (as determined by treating doctor of medicine [MD]) related to surgery
All adverse events (excluding alopecia, acne, rash) due to agents administered more than 2 weeks earlier should recover to =< grade 1; patients with hematologic malignancies are expected to have hematologic abnormalities at study entry; these abnormalities which are thought to be primarily related to the underlying leukemia, are not considered to be toxicities (adverse events [AE]) and do not need to resolve to =< grade 1
Patients may have received prior surgery (for both the primary and stage IV disease); all adverse events associated with prior surgery must have resolved to =< grade 1 prior to registration
Patients are excluded from re-induction if they have experienced any related dose-limiting toxicities, delayed dosing beyond 35 days due to tremelimumab-related adverse events (AEs), or have been taken off treatment due to toxicity
Patients who have had systemic chemotherapies or targeted therapies within 3 weeks or radiotherapy within 2 weeks prior to entering the study or those patients whose adverse events from prior therapies have not recovered to =< grade 1 (other than grade 2 neuropathy, lymphopenia and alopecia which are permitted)
Resolution of prior therapy acute adverse events.
Prior treatment with an anti-cytotoxic T-lymphocyte-associated protein (CTLA)-4 antibody if treatment failure was due to adverse events (AEs); if a subject was discontinued from the prior anti-CTLA-4 treatment due to an AE or serious adverse event (SAE), regardless of the type of event, that discontinuation constitutes an exclusion criterion; if AEs were serious enough to require a subject’s withdrawal from prior treatment, the subject should be excluded from this study
Patient did not discontinue due to a Grade ?3 related adverse event
Received prior TKI treatment within 7 days prior to receiving the first dose of ponatinib, or have not recovered from adverse events (except alopecia) due to agents previously administered.
Had a prior anti-cancer monoclonal antibody (except immune CPI in the case of melanoma subjects) within 30 days prior to start of study treatment, or failure to recover to CTCAE Grade 1 or better from the adverse events of prior therapies
Patients may have had prior chemotherapy or immunotherapy or radiation therapy. Any drug-related adverse events (AEs) identified during prior therapy must have been well-controlled (typically resolution to ? Grade 2), or resolved upon investigator review prior to initiation of the study therapy.
Unresolved immune related adverse events following prior biological therapy.
Has ongoing acute clinical adverse events NCI CTCAE Grade >1 resulting from prior cancer therapies (except alopecia, TKI-related hand-foot syndrome, or thyroid dysfunction).
Patients must not have received systemic therapy or radiotherapy within the preceding 3 weeks; patients must have recovered from adverse events from previous therapy by the time of registration
Grade 3 (or higher) adverse event assessed as treatment-related at any time during the course of treatment under Protocol 8400-401.
Failure to recover to grade 1 or less all prior adverse events.
Grade 2 hepatic function related adverse event that persisted more than 1 week, was considered related to immunotherapy, or required treatment discontinuation or immunosuppressive therapy
Participants with worsening adverse events
All adverse events from the procedure have resolved or have been deemed irreversible and the patient meets inclusion criteria.
Any history of an immune-related Grade 4 adverse event attributed to prior CIT (other than endocrinopathy managed with replacement therapy or asymptomatic elevation of serum amylase or lipase)
Any history of an immune-related Grade 3 adverse event attributed to prior CIT (other than hypothyroidism managed with replacement therapy) that resulted in permanent discontinuation of the prior immunotherapeutic agent and/or occurred less than or equal to (<=) 6 months prior to Cycle 1 Day 1
Adverse events from prior anti-cancer therapy that have not resolved to Grade <=1 except for alopecia, vitiligo, or endocrinopathy managed with replacement therapy
All immune-related adverse events related to prior CIT (other than endocrinopathy managed with replacement therapy or stable vitiligo) must have resolved completely to baseline
Patient has not recovered to baseline or less than Grade 1 from non-hematologic adverse events related to any anticancer therapy received prior to signing informed consent on the Treatment Extension study, with the exception of hair loss.
Patient who had not recovered to grade 1 or better from any adverse events (except alopecia, nausea, vomiting) related to previous antineoplastic therapy before screening procedures are initiated, as allowed in inclusion criteria
Any subject with the following reported drug-related adverse events on anti- Cytotoxic T-Lymphocyte Antigen 4 (anti-CTLA4) will not be permitted on study: hepatic, diarrhea/colitis or endocrine adverse events (AE)s Grade ? 2, any other non-laboratory immune-related AE ? Grade 3. Subjects must have minimum 9 week washout period between the last dose of anti-CTLA4 and the first dose Urelumab (BMS-663513)
All adverse events of any prior chemotherapy, surgery, or radiotherapy not resolved
Anatomic or physiologic abnormality that could lead to significant postoperative adverse events
Available for follow-up of their disease after treatment until progressive disease is documented and resolution of related adverse events until < grade 2
Skin conditions that require consistent use of topical corticosteroids or other local or systemic therapy that may interfere with interpretation or description of skin-related adverse events linked to vaccination
Ongoing medically significant adverse events from previous treatment, regardless of the time period
Any prior adverse events associated with prior MRI that are not related to injection of contrast agents or other medicines
ongoing grade 2 or greater toxicities due to previous therapies. However, tolerable grade 2 adverse (e.g. neuropathy) events may be allowed at the discretion of the investigator.
Subjects with grade 2 or greater toxicities due to previous therapies (subject to the additional laboratory abnormalities listed below); however, tolerable grade 2 adverse (e.g. residual neuropathy from taxane or oxaliplatin) events may be allowed at the discretion of the investigator
Have not recovered from adverse events due to other pharmaceutical or diagnostic agents.
The patient has not recovered to grade ? 1 adverse events (AEs) due to investigational drugs or other medications, administered more than 2 weeks prior to the first dose of study drug, with the exception of neurotoxicity attributed to oxaliplatin or taxanes, which must have recovered to < 2 prior to study initiation.
Completed a prior therapy less than (<) 2 weeks prior to first dose and for whom adverse events (AEs) related to prior therapy had not returned to baseline or improved to Grade 1.
Prior systemic anticancer therapy within 4 weeks prior to enrollment or who has not recovered (i.e. ? Grade 1 or baseline grade) from adverse events due to a previously administered agent
